Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYun WangCLChun-Hua LiRGRobert Gale

Discussion

Loading...

Member takes

Overview

Sensitivity analysis finds MRD testing shows weak prediction of progression-free survival in chronic lymphocytic leukaemia, indicating the need for cautious interpretation.

Key Points

  • This research aims to determine the accuracy of measurable residual disease testing as a predictor of progression-free survival in chronic lymphocytic leukaemia therapies.
  • Analyzed 41 trials involving chronic lymphocytic leukaemia and measurable residual disease testing.
  • Utilized Bayesian Weibull accelerated failure time models for individual-level analyses.
  • Employed trial-level correlations using weighted Spearman rank tests and weighted least squares regression.
  • Subjects with detectable MRD had a higher risk of progression and death compared to undetectable MRD.
  • Bone marrow MRD testing showed stronger predictive accuracy for progression-free survival than blood testing.
  • Sensitivity analyses indicated MRD testing's predictive ability varies significantly by therapy type, notably lower for BTK inhibitors.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce6https://doi.org/10.1182/blood-2025-2132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025
  2. 2Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia2024 · 1 citations
  3. 3Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.2026 · 3 citations
  4. 4Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  5. 5What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025